INOVIQ LTD — Board/Management Information 2017

Jul 19, 2017

==> picture [155 x 46] intentionally omitted <==

BARD1 APPOINTS DR SAM JANES TO ADVISORY BOARD

• International respiratory medicine expert, Dr Samuel Janes, has been appointed as a member of BARD1’s Advisory Board.

• Dr Janes will provide independent scientific and clinical advice to guide BARD1’s research, development and business programs.

Perth, Australia, 20 July 2017: Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) ( BARD1 LSL or the Company ) is pleased to announce the appointment of leading respiratory physician, Dr Samuel Janes, as a member of its Advisory Board.

Dr Samuel Janes MBBS MRCP MSc PhD is an outstanding clinical scientist, respiratory physician, and a Wellcome Senior Fellow in Clinical Science, Professor of Respiratory Medicine and Head of Respiratory Research Department at the University College London Hospitals (UCLH). Dr Janes qualified from the University of London as a medical doctor in 1991 gaining a BSc (Hons) and MBBS, then trained in respiratory medicine at several hospitals, completed an MSc (Distinction) in Respiratory Medicine in 1999, gained his CCST in Respiratory and General Medicine in 2004, and a PhD in integrin adhesion molecules and cancer cell survival in 2004.

Dr Janes is recognised internationally for his research into lung cancer, mesothelioma, bronchoscopy and early lung cancer detection. He is a lead investigator in several diagnostic and therapeutic clinical studies in lung cancer, and is strongly committed to facilitating the translation of laboratory findings into the clinic. He has published over 100 clinical and scientific papers in the field of respiratory disease, and has sat on the British Thoracic Society, British Lung Foundation, and Roy Castle Lung Cancer Foundation scientific committees. He was awarded the European Thoracic Oncology Investigator of the Year in 2010.

Dr Janes said: “My research focus is the pathogenesis, early detection and novel treatment of lung cancer to improve survival and patient experience. BARD1 is potentially an important diagnostic marker and therapeutic target in the fight against cancer, and I am confident that my respiratory medicine expertise and clinical research experience will add significant value to the ongoing evaluation, development and validation of the BARD1 Tests for early detection of cancer.”

Leearne Hinch, BARD1 CEO, said: “We welcome Dr Sam Janes as a member of our Advisory Board and greatly look forward to working with him. Dr Janes brings a wealth of experience in the early detection and treatment of lung cancer when it is potentially curable. His extensive respiratory medicine expertise, clinical development experience, and international industry networks will provide invaluable guidance for BARD1’s research, development and business programs.”

Under the Consultation and Advisory Board Agreement, Dr Janes will be granted two million (2,000,000) Options to acquire fully paid shares in the capital of the Company at an exercise price of $0.0128, with a 4-year expiry that shall vest upon completion of 12-months service. Issue of the Options is subject to the Company receiving Shareholder Approval.

• ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg	Dr Leearne Hinch
Chairman	CEO
E peter@bard1.com	E leearne@bard1.com
	M+61 400 414 416

BARD1 Life Sciences Limited (ABN 58 009 070 384) Headquarters | Harry Perkins Institute, L2/QQ Block, 6 Verdun St, Nedlands WA 6009, Australia Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E info@bard1.com | W www.bard1.com

BARD1 | ASX Announcement

2

ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. Its lead product, the BARD1 Lung Cancer Test, is a blood test in development for early detection of lung cancer, utilising novel tumour markers and a proprietary algorithm. The company’s pipeline also includes the BARD1 Ovarian Cancer Test in development for early detection of ovarian cancer, and high-value diagnostic and therapeutic projects at research-stage for multiple cancers. BARD1 LSL is committed to transforming the early detection and prevention of cancer to help improve patients' lives.

BARD1 LSL | ASX Release